Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide

被引:17
|
作者
Zade, Amir Ebrahimi [1 ]
Haghighi, Seyedhamidreza Shahabi [1 ]
Soltani, Madjid [2 ,3 ,4 ,5 ]
机构
[1] Amirkabir Univ Technol, Fac Ind Engn & Syst Management, Tehran, Iran
[2] KN Toosi Univ Technol, Fac Mech Engn, Tehran 1969764499, Iran
[3] KN Toosi Univ Technol, Adv Bioengn Initiat Ctr, Computat Med Ctr, Tehran, Iran
[4] Univ Waterloo, Ctr Biotechnol & Bioengn CBB, Waterloo, ON, Canada
[5] Univ Waterloo, Dept Elect & Comp Engn, Waterloo, ON, Canada
关键词
Glioblastoma multiforme; Treatment scheduling; Reinforcement learning; Multi scale modeling; Temozolomide; CARCINOMA IN-SITU; BRAIN-TUMORS; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ADJUVANT TEMOZOLOMIDE; INDIVIDUAL PATIENTS; MATHEMATICAL-MODEL; GLIOMA GROWTH; SOLID TUMOR; PHASE-II; RADIOTHERAPY;
D O I
10.1016/j.cmpb.2020.105443
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Background: : Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults and Temozolomide (TMZ) is an effective chemotherapeutic agent for its treatment. In Silico models of GBM growth provide an appropriate foundation for analysis and comparison of different regimens. We propose a mathematical frame for patient specific design of optimal chemotherapy regimens for GBM patients. Methods: : The proposed frame includes online interaction of a virtual GBM with an optimizing agent. Spatiotemporal dynamics of GBM growth and its response to TMZ are simulated with a three dimensional hybrid cellular automaton. Q learning is tailored to the virtual GBM for treatment optimization aimed at minimizing tumor size at the end of treatment course. Q learning consists of a learning agent that interacts with the virtual GBM. System state is affected by the agent decisions and the obtained rewards guide Q learning to the optimal schedule. Results: : Computational results confirm that the optimal chemotherapy schedule depends on some patient specific parameters including body weight, tumor size and its position in the brain. Furthermore, the algorithm is used for scheduling 2100 mg of TMZ on a virtual GBM and the obtained schedule is to administer150 mg of TMZ every other day. The obtained schedule is compared to the standard 7/14 regimen and the results show that it is superior to the 7/14 regimen in minimizing tumor size. Conclusion: : The proposed frame is an appropriate decision support system for patient specific design of TMZ administration regimens on GBM patients. Also, since the obtained optimal schedule outperforms the standard 7/14 regimen, it is worthy of further clinical testing. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme
    Fabian Baumann
    Miroslava Bjeljac
    Spyros S. Kollias
    Brigitta G. Baumert
    Sebastian Brandner
    Valentin Rousson
    Yasuhiro Yonekawa
    René L. Bernays
    Journal of Neuro-Oncology, 2004, 67 : 191 - 200
  • [42] Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme
    Baumann, F
    Bjeljac, M
    Kollias, SS
    Baumert, BG
    Brandner, S
    Rousson, V
    Yonekawa, Y
    Bernays, RL
    JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) : 191 - 200
  • [43] Identification of senolytic agents for sequential treatment of glioblastoma with temozolomide
    Beltzig, Lea
    Stratenwerth, Bjoern
    Christmann, Markus
    Kaina, Bernd
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 45 - 45
  • [44] Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma
    Baritchii, Adriana
    Jurj, Anca
    Soritau, Olga
    Tomuleasa, Ciprian
    Raduly, Layos
    Zanoaga, Oana
    Cernea, Dana
    Braicu, Cornelia
    Neagoe, Ioana
    Florian, Ioan Stefan
    JOURNAL OF BUON, 2016, 21 (01): : 199 - 207
  • [45] Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
    Cruz, Joao Victor Roza
    Batista, Carolina
    Afonso, Bernardo de Holanda
    Alexandre-Moreira, Magna Suzana
    Dubois, Luiz Gustavo
    Pontes, Bruno
    Moura Neto, Vivaldo
    Mendes, Fabio de Almeida
    CANCERS, 2022, 14 (13)
  • [46] Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme
    Nagasawa, Daniel T.
    Chow, Frances
    Yew, Andrew
    Kim, Won
    Cremer, Nicole
    Yang, Isaac
    NEUROSURGERY CLINICS OF NORTH AMERICA, 2012, 23 (02) : 307 - +
  • [47] REPURPOSING ITRACONAZOLE AND PYRIMETHAMINE WITH TEMOZOLOMIDE AS A COMBINATORIAL TREATMENT FOR GLIOBLASTOMA
    Lootens, T.
    Vandersteene, J.
    Pinson, H.
    Boterberg, T.
    Vermeirssen, V.
    De Wever, O.
    De Smet, F.
    Raedt, R.
    NEURO-ONCOLOGY, 2024, 26 : V135 - V135
  • [48] Optimal User Scheduling in Multi Antenna System Using Multi Agent Reinforcement Learning
    Naeem, Muddasar
    Coronato, Antonio
    Ullah, Zaib
    Bashir, Sajid
    Paragliola, Giovanni
    SENSORS, 2022, 22 (21)
  • [49] Polymer zwitterion-temozolomide conjugates for glioblastoma treatment
    Ward, Sarah
    Skinner, Matthew
    Saha, Banishree
    Emrick, Todd
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [50] Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment
    Iturrioz-Rodriguez, Nerea
    Sampron, Nicolas
    Matheu, Ander
    THERANOSTICS, 2023, 13 (09): : 2734 - 2756